Esketamine is an effective antidepressant for the management of treatment-resistant depression (TDR). It is a highly specialised medication that traditionally has only been available through clinical trials, until it was recently approved for clinical use by the Therapeutic Goods Authority (TGA).
Esketamine is delivered by intranasal spray in a clinic setting supervised by trained staff. We offer a case management-based approach to the treatment of patients on esketamine. This means patients are case managed by a psychiatrist, and a mental health nurse while offering periodic correspondence to the patient’s treating team. Patients are generally seen twice a week with their esketamine medications administered within the clinic under the supervision of a health professional. We have a well-established structure for esketamine provision in our clinics with specialist support systems in place.
To be eligible to participate in the esketamine program, you must meet the following criteria:
